93 related articles for article (PubMed ID: 16303620)
1. Regulation of the sphingolipid signaling pathways in the growing and hypoxic rat heart.
El Alwani M; Usta J; Nemer G; El Sabban M; Nasser M; Bitar H; Souki R; Dbaibo GS; Bitar FF
Prostaglandins Other Lipid Mediat; 2005 Dec; 78(1-4):249-63. PubMed ID: 16303620
[TBL] [Abstract][Full Text] [Related]
2. Measurement of ceramide and sphingolipid metabolism in tumors: potential modulation of chemotherapy.
Modrak DE
Methods Mol Med; 2005; 111():183-94. PubMed ID: 15911980
[TBL] [Abstract][Full Text] [Related]
3. Increase in sphingolipid catabolic enzyme activity during aging.
Sacket SJ; Chung HY; Okajima F; Im DS
Acta Pharmacol Sin; 2009 Oct; 30(10):1454-61. PubMed ID: 19749786
[TBL] [Abstract][Full Text] [Related]
4. Activation of sphingolipid turnover and chronic generation of ceramide and sphingosine in liver during aging.
Lightle SA; Oakley JI; Nikolova-Karakashian MN
Mech Ageing Dev; 2000 Dec; 120(1-3):111-25. PubMed ID: 11087909
[TBL] [Abstract][Full Text] [Related]
5. Modulation of total ceramide and constituent ceramide species in the acutely and chronically hypoxic mouse heart at different ages.
Noureddine L; Azzam R; Nemer G; Bielawski J; Nasser M; Bitar F; Dbaibo GS
Prostaglandins Other Lipid Mediat; 2008 Jun; 86(1-4):49-55. PubMed ID: 18400538
[TBL] [Abstract][Full Text] [Related]
6. Human meconium contains significant amounts of alkaline sphingomyelinase, neutral ceramidase, and sphingolipid metabolites.
Duan RD; Cheng Y; Jönsson BA; Ohlsson L; Herbst A; Hellström-Westas L; Nilsson A
Pediatr Res; 2007 Jan; 61(1):61-6. PubMed ID: 17211142
[TBL] [Abstract][Full Text] [Related]
7. Sphingomyelin metabolism is developmentally regulated in rat lung.
Longo CA; Tyler D; Mallampalli RK
Am J Respir Cell Mol Biol; 1997 May; 16(5):605-12. PubMed ID: 9160843
[TBL] [Abstract][Full Text] [Related]
8. Bimodal effect of advanced glycation end products on mesangial cell proliferation is mediated by neutral ceramidase regulation and endogenous sphingolipids.
Geoffroy K; Wiernsperger N; Lagarde M; El Bawab S
J Biol Chem; 2004 Aug; 279(33):34343-52. PubMed ID: 15184394
[TBL] [Abstract][Full Text] [Related]
9. Sphingolipid metabolism in the regulation of bioactive molecules.
Luberto C; Hannun YA
Lipids; 1999; 34 Suppl():S5-11. PubMed ID: 10419081
[No Abstract] [Full Text] [Related]
10. Modulation of ceramide content and lack of apoptosis in the chronically hypoxic neonatal rat heart.
Bitar FF; Bitar H; El Sabban M; Nasser M; Yunis KA; Tawil A; Dbaibo GS
Pediatr Res; 2002 Feb; 51(2):144-9. PubMed ID: 11809907
[TBL] [Abstract][Full Text] [Related]
11. Effects of fat, beef and fiber in diets on activities of sphingomyelinase, ceramidase and caspase-3 in rat colonic mucosa.
Yang L; Mutanen M; Cheng Y; Duan RD
Med Princ Pract; 2002; 11(3):150-6. PubMed ID: 12138298
[TBL] [Abstract][Full Text] [Related]
12. Tissue-specific ceramide response in the chronically hypoxic rat model mimicking cyanotic heart disease.
Bitar FF; Mroueh S; El Khatib M; Bitar H; Tarrabain M; El Sabban M; Obeid M; Nasser M; Dbaibo GS
Prostaglandins Other Lipid Mediat; 2003 Nov; 72(3-4):155-63. PubMed ID: 14674627
[TBL] [Abstract][Full Text] [Related]
13. PPARalpha agonist induces the accumulation of ceramide in the heart of rats fed high-fat diet.
Baranowski M; Błachnio A; Zabielski P; Górski J
J Physiol Pharmacol; 2007 Mar; 58(1):57-72. PubMed ID: 17440226
[TBL] [Abstract][Full Text] [Related]
14. Sphingolipids and response to chemotherapy.
Dimanche-Boitrel MT; Rebillard A
Handb Exp Pharmacol; 2013; (216):73-91. PubMed ID: 23563652
[TBL] [Abstract][Full Text] [Related]
15. Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk.
Samad F; Hester KD; Yang G; Hannun YA; Bielawski J
Diabetes; 2006 Sep; 55(9):2579-87. PubMed ID: 16936207
[TBL] [Abstract][Full Text] [Related]
16. Dysregulated sphingolipid metabolism in endometriosis.
Lee YH; Tan CW; Venkatratnam A; Tan CS; Cui L; Loh SF; Griffith L; Tannenbaum SR; Chan JK
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1913-21. PubMed ID: 24960545
[TBL] [Abstract][Full Text] [Related]
17. Aziridine ring opening for the synthesis of sphingolipid analogues: inhibitors of sphingolipid-metabolizing enzymes.
Alcaide A; Llebaria A
J Org Chem; 2014 Apr; 79(7):2993-3029. PubMed ID: 24641332
[TBL] [Abstract][Full Text] [Related]
18. Ceramide synthase inhibition by fumonisin B1 treatment activates sphingolipid-metabolizing systems in mouse liver.
He Q; Suzuki H; Sharma N; Sharma RP
Toxicol Sci; 2006 Dec; 94(2):388-97. PubMed ID: 16960033
[TBL] [Abstract][Full Text] [Related]
19. Sphingolipids in psychiatric disorders and pain syndromes.
Mühle C; Reichel M; Gulbins E; Kornhuber J
Handb Exp Pharmacol; 2013; (216):431-56. PubMed ID: 23563670
[TBL] [Abstract][Full Text] [Related]
20. Long- and short-term effects of thyroxine on sphingolipid metabolism in rat liver.
Babenko NA
Med Sci Monit; 2005 May; 11(5):BR131-138. PubMed ID: 15874883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
